BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company founded in 1996 and incorporated in California, specializing in developing and commercializing therapies for rare genetic diseases. The company went public in 1999 and has evolved from a small biotech startup into a leading player in the rare disease pharmaceutical market. BioMarin focuses on conditions that affect small patient populations but cause severe, life-threatening symptoms, often targeting genetic disorders where patients have limited or no treatment options. The company has successfully brought multiple therapies to market and maintains a robust pipeline of investigational treatments, primarily focusing on enzyme replacement therapies and gene therapies for inherited metabolic disorders.